Host Gene Expression Biomarkers for Bacterial Infection Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for bacterial infections, such as sepsis caused by Staphylococcus aureus, are slow and inaccurate, leading to delayed antibiotic administration and unnecessary antimicrobial resistance.
Innovation Solution
A diagnostic assay that determines gene expression levels of specific biomarkers in a subject, comparing them to control levels to differentiate between bacterial infections like Staphylococcus aureus and Escherichia coli bloodstream infections, using an algorithm to provide a weighted value for accurate classification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic approaches (blood cultures) are used to identify bacterial pathogens, then diagnostic accuracy is improved, but diagnostic time is excessively long and sensitivity is limited
Solution Approach 1:
The invention extracts and measures specific host gene expression biomarkers (such as IL-6, TNF-alpha, IL-1beta) from patient samples using PCR or microarray techniques, rather than relying on traditional pathogen isolation methods. This extraction of key diagnostic indicators from the complex host response enables rapid and accurate differentiation between Gram-positive and Gram-negative bacterial infections within hours, resolving the contradiction between diagnostic accuracy and time consumption
Solution Approach 2:
The invention uses host gene expression profiles as an intermediary marker to indirectly detect and differentiate bacterial pathogens. Instead of directly identifying the pathogen (which is time-consuming), the method measures the host's inflammatory response signature, which serves as a mediator that rapidly indicates the type of bacterial infection present, thereby achieving both speed and accuracy
2Loss of time
If empirical antibiotic treatment is initiated without accurate diagnosis, then treatment time is reduced, but antimicrobial resistance increases due to inappropriate antibiotic use
Solution Approach 1:
The invention performs preliminary diagnostic action by rapidly identifying the type of bacterial infection (Gram-positive vs. Gram-negative) through host gene expression analysis before initiating antibiotic treatment. This preliminary classification enables clinicians to select appropriate antibiotic classes in advance, reducing treatment delays while ensuring the chosen antibiotics are targeted correctly, thereby preventing the development of antimicrobial resistance
Solution Approach 2:
The invention changes the diagnostic parameter from direct pathogen detection to host gene expression measurement. By measuring expression levels of specific genes (e.g., IL-6 for Gram-negative, TNF-alpha for Gram-positive), the method provides rapid classification that guides appropriate antibiotic selection, achieving both rapid treatment initiation and reduced inappropriate antibiotic use
3Measurement precision
If comprehensive pathogen identification methods are used, then diagnostic accuracy is improved, but device complexity and cost increase
Solution Approach 1:
The invention extracts and measures only the most informative host gene expression biomarkers relevant to differentiating bacterial types, rather than attempting to detect all possible pathogens. This selective measurement of key genes (such as IL-6, TNF-alpha, IL-1beta, CXCL8) using PCR or microarray technology achieves accurate Gram-positive vs. Gram-negative differentiation with a relatively simple and cost-effective assay design
Solution Approach 2:
The invention applies partial action by focusing on measuring a specific subset of host genes that provide sufficient discriminatory power for clinical decision-making. Rather than comprehensively identifying every possible pathogen, the method measures enough gene expression markers to accurately distinguish between Gram-positive and Gram-negative infections, achieving adequate diagnostic precision with reduced complexity
Data Source
AI summary
Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.